Literature DB >> 239965

Antileukotactic properties of tumor cells.

J P Brozna, P A Ward.   

Abstract

A chemotactic factor inactivator (CFI) has been found in extracts of Walker and Novikoff tumor cells maintained in rats. The CFI directly inactivates the bacterial chemotactic factor as well as the leukotactic activity (fro both neutrophils and monocytes) associated with C3 and C5 fragments and with culture fluids of lectin-stimulated lymphoid cells. The inactivation of the bacterial chemotactic factor is temperature and pH dependent. Subcellular fractionation procedures indicate that CFI is largely associated with the microsomal and cytosol fractions of tumor cells. CFI activity is also found in rat neutrophils, alveolar macrophages, and in extracts of liver, spleen, and kidney from normal animals. CFI derived from normal tissues also directly inactivates the bacterial chemotactic factor and has the ability to inactivate chemotactic activity associated with C3 and C5 fragments. A feature of the tumor-associated CFI is its presence in ascitic fluids of animals bearing tumor cells and the relative absence of any CFI activity in acute inflammatory exudates. The finding of the tumor-associated CFI may explain, at least in part, the tendency of malignant tumor cells to suppress cellular inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 239965      PMCID: PMC301909          DOI: 10.1172/JCI108131

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  DELAYED HYPERSENSITIVITY RESPONSE TO DNFB IN SICK AND HEALTHY PERSONS.

Authors:  A G LEVIN; E F MCDONOUGH; D G MILLER; C M SOUTHAM
Journal:  Ann N Y Acad Sci       Date:  1964-11-30       Impact factor: 5.691

2.  Inhibition of cellular adhesion and pseudopodia formation by a dialysable factor from tumour fluids.

Authors:  B HOLMBERG
Journal:  Nature       Date:  1962-07-07       Impact factor: 49.962

3.  A comparative study of the incidence of anergy in patients with carcinoma, leukemia, hodgkin's disease and other lymphomas.

Authors:  D LAMB; F PILNEY; W D KELLY; R A GOOD
Journal:  J Immunol       Date:  1962-10       Impact factor: 5.422

4.  Inflammation and prognosis in breast cancer; a search for host resistance.

Authors:  J W BERG
Journal:  Cancer       Date:  1959 Jul-Aug       Impact factor: 6.860

5.  The inflammatory response to a foreign body within transplantable tumors.

Authors:  M J MAHONEY; J LEIGHTON
Journal:  Cancer Res       Date:  1962-04       Impact factor: 12.701

Review 6.  The separation and characterization of subcellular particles.

Authors:  C De Duve
Journal:  Harvey Lect       Date:  1965

7.  Chemotactic factor inactivator in normal human serum.

Authors:  J L Berenberg; P A Ward
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

8.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  C3 leukotactic factors produced by a tissue protease.

Authors:  J H Hill; P A Ward
Journal:  J Exp Med       Date:  1969-09-01       Impact factor: 14.307

10.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  17 in total

1.  In vitro and in vivo production of chemotactic inhibitors by tumor cells.

Authors:  M C Cohen; J P Brozna; P A Ward
Journal:  Am J Pathol       Date:  1979-03       Impact factor: 4.307

2.  Characterization of the protease activity in the chemotactic factor inactivator.

Authors:  P A Ward; J Ozols
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

3.  Chemotactic factor inactivators of human granulocytes.

Authors:  J P Brozna; R M Senior; D L Kreutzer; P A Ward
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

4.  Normalization of defective monocyte chemotaxis during chemotherapy in patients with small cell anaplastic carcinoma of the lung.

Authors:  H Nielsen; J Bennedsen; P Dombernowsky
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  A chemotactic inhibitor in synovial fluid.

Authors:  Y Matzner; R E Partridge; B M Babior
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

6.  Inflammation and host resistance to pathogens.

Authors:  R M Fauve
Journal:  Intensive Care Med       Date:  1977-12       Impact factor: 17.440

7.  Defects of serum chemoattraction and polymorphonuclear leucocyte movement in patients with primary hepatocellular carcinoma.

Authors:  A G Yousif-Kadaru; R J Wyke; I A Rajkovic; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

8.  Effect of L1210 leukemia on the susceptibility of mice to Candida albicans infections.

Authors:  J A Johnson; B H Lau; R L Nutter; J M Slater; C E Winter
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

9.  Serum inhibitory effect on myeloperoxidase in human cancer.

Authors:  B Senelar; R Michel; J Tournamille; H Vannereau; M J Escola; J Taib; A Craste de Paulet
Journal:  Br J Exp Pathol       Date:  1982-06

10.  Suppression of acute and chronic inflammation in tumor-bearing rats.

Authors:  J P Brozna; P A Ward
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.